World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
109
Citations
48910
World Ranking
5730
National Ranking
3081

Peter H. Wiernik publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Peter H. Wiernik sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 747 publications — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Peter H. Wiernik D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Peter H. Wiernik sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 109 D-Index — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 1977 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Peter H. Wiernik is affiliated with the Cancer Research Foundation of New York in the United States. Their research primarily focuses on medicine, with a concentration in hematology, public health, environmental and occupational health, oncology, genetics, and pulmonary and respiratory medicine.

The main topics covered in their work include:

  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Retinoids in leukemia and cellular processes
  • Childhood Cancer Survivors' Quality of Life
  • Lung Cancer Diagnosis and Treatment

Recent significant papers authored or co-authored by Peter H. Wiernik include:

  • Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL, 2021, Blood
  • The importance of low-dose CT screening to identify emphysema in asymptomatic participants with and without a prior diagnosis of COPD, 2021, Clinical Imaging
  • CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials, 2021, Blood Advances
  • Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2, 2021, Journal of Investigative Medicine
  • The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era, 2020, Biology of Blood and Marrow Transplantation

Frequent co-authors include:

  • Hillard M. Lazarus
  • Mark R. Litzow
  • Martin S. Tallman
  • David I. Marks
  • Elisabeth Paietta

Publications by Peter H. Wiernik appear most often in the following venues:

  • Journal of Investigative Medicine
  • UNC Libraries
  • British Journal of Haematology
  • Blood
  • Bone Marrow Transplantation

Peter H. Wiernik received the Fellow of the American Association for the Advancement of Science (AAAS) award in 1977.

Best Publications

  • Hypersensitivity reactions from taxol.

    R B Weiss;R C Donehower;P H Wiernik;T Ohnuma

  • All-trans-Retinoic Acid in Acute Promyelocytic Leukemia

    Martin S. Tallman;Janet W. Andersen;Charles A. Schiffer;Frederick R. Appelbaum

  • In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

    Anthony H. Goldstone;Susan M. Richards;Hilliard M. Lazarus;Martin S. Tallman

  • Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993

    Jacob M. Rowe;Georgina Buck;Alan Kenneth Burnett;Raj Chopra

  • Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission

    Peter A. Cassileth;David P. Harrington;Frederick R. Appelbaum;Hillard M. Lazarus

  • Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens.

    Stephen C. Schimpff;Viola Mae Young;William H. Greene;Gerald D. Vermeulen

  • Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

    Anthony V. Moorman;Christine J. Harrison;Georgina A.N. Buck;Sue M. Richards

  • Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study

    J Yates;O Glidewell;P Wiernik;Cooper

  • Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia

    Peter H. Wiernik;Phillip L.C. Banks;Delvyn C. Case;Zalmen A. Arlin

  • Phase I clinical and pharmacokinetic study of taxol

    Peter H. Wiernik;Edward L. Schwartz;Janice J. Strauman;Janice P. Dutcher

  • Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

    KR Rai;JF Holland;OJ Glidewell;V Weinberg

  • Neurotoxicity of Commonly Used Antineoplastic Agents

    Howard D. Weiss;Michael D. Walker;Peter H. Wiernik

  • Staphylococcus epidermidis: An Increasing Cause of Infection in Patients with Granulocytopenia

    James C. Wade;Stephen C. Schimpff;Kathryn A. Newman;Peter H. Wiernik

  • Treatment of Invasive Aspergillosis: Relation of Early Diagnosis and Treatment to Response

    Joseph Aisner;Stephen C. Schimpff;Peter H. Wiernik

  • Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high‐dosage schedule

    Robert S. Benjamin;Peter H. Wiernik;Nicholas R. Bachur

  • Clinical presentation of infection in granulocytopenic patients.

    Edward A. Sickles;William H. Greene;Peter H. Wiernik

  • Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

    Peter H. Wiernik;Izidore S. Lossos;Joseph M. Tuscano;Glen Justice

  • Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer Cells: A Phase II Clinical Trial

    Fisher Ri;Coltman Ca;Doroshow Jh;Rayner Aa

  • High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.

    Kathryn G. Roberts;Zhaohui Gu;Debbie Payne-Turner;Kelly McCastlain

  • Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis.

    Schimpff Sc;Greene Wh;Young Vm;Fortner Cl

Frequent Co-Authors

Martin S. Tallman
Martin S. Tallman Northwestern University
Jacob M. Rowe
Jacob M. Rowe Technion – Israel Institute of Technology
Joseph A. Sparano
Joseph A. Sparano Albert Einstein College of Medicine
Hillard M. Lazarus
Hillard M. Lazarus Case Western Reserve University
John M. Bennett
John M. Bennett University of Rochester Medical Center
Charles A. Schiffer
Charles A. Schiffer Wayne State University
Mark R. Litzow
Mark R. Litzow Mayo Clinic
Gordon W. Dewald
Gordon W. Dewald Mayo Clinic
Clara D. Bloomfield
Clara D. Bloomfield The Ohio State University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine can open up a range of educational and professional options beyond the traditional MD route. Many students today are exploring degrees that offer flexibility and specialized skills, especially through online programs.

For those interested in healthcare administration, there are cheapest mha programs online that provide the management expertise needed in hospitals and clinics. If you wish to advance your nursing credentials, several msn to dnp programs online are available, allowing nurses to step into leadership or advanced practice roles.

Future pharmacists can benefit from pharmacy school online accredited programs. These accredited online degrees make it possible to pursue a doctorate in pharmacy while maintaining work or personal commitments.

Additionally, the rapidly growing field of health informatics is accessible through health information technology programs online. This pathway is ideal for those who want to blend healthcare with information systems and data management.

Choosing these alternate healthcare degrees online can lead to rewarding careers in a dynamic healthcare landscape.

Best Scientists Citing Peter H. Wiernik

Trending Scientists

Recently Published Articles